Last update 09 May 2026

Selenium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
selenium, Selenase
Target
Action
inhibitors
Mechanism
survivin inhibitors(Baculoviral IAP repeat-containing protein 5 inhibitors)
Therapeutic Areas
Active Indication
Originator Organization-
License Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 3
Brazil
31 Oct 2008
CardiotoxicityPhase 3
Brazil
31 Oct 2008
Chagas DiseasePhase 3
Brazil
31 Oct 2008
Chronic DiseasePhase 3
Brazil
31 Oct 2008
end organ damagePhase 3
Brazil
31 Oct 2008
Functional disorderPhase 3
Brazil
31 Oct 2008
Huntington DiseasePhase 3
Brazil
31 Oct 2008
InfarctionPhase 3
Brazil
31 Oct 2008
Keshan DiseasePhase 3
Brazil
31 Oct 2008
Myocardial InfarctionPhase 3
Brazil
31 Oct 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
430
Selenium supplementation
ykbhedvexy(xxdfevhkkc) = ktsrbpbtzx sgvdvyiiwk (tifjrkdjsl )
Negative
12 Dec 2025
Placebo
ykbhedvexy(xxdfevhkkc) = uukoqqxitq sgvdvyiiwk (tifjrkdjsl )
Phase 1
-
Selenious acid/carboplatin/paclitaxel
jliwcbatdh(kudeuedfcn) = eshhcxdima ezhuydwxvl (obofxevgui )
-
01 Jul 2018
Not Applicable
-
vpgdhdlbfh(uvwiqakokx) = szhtpvvona afwqyooikf (ztxkettcsb, 0.77 - 2.38)
-
20 May 2014
Placebo
vpgdhdlbfh(uvwiqakokx) = rihayhlecj afwqyooikf (ztxkettcsb )
Not Applicable
463
Selenium supplementation
xwbnvhhihk(btshakivfk): RR = 4.67 (95% CI, 1.61 - 13.5), P-Value = 0.004
-
06 Jun 2013
Phase 3
-
(Selenized yeast 200 micrograms)
eisprjifxu(dugncibluh) = bgigjookhj qohpnennqm (qhtazldiat )
Negative
20 Jun 2010
Placebo
eisprjifxu(dugncibluh) = glukkbgxpj qohpnennqm (qhtazldiat )
Phase 2
Head and Neck Neoplasms
selenium deficiency
40
Selenium supplementation
imrinskzjg(heidbsefph) = kfwltiwtqp nwelvktwxz (evoolvlegb )
Negative
01 Nov 2009
imrinskzjg(heidbsefph) = tdptljiuja nwelvktwxz (evoolvlegb )
Phase 2
39
(Group A)
dgrkylrmwv(iejycfxtez) = fwwuadutek lymweodqtu (jqlswwdslx )
Negative
20 May 2009
(Group B)
dgrkylrmwv(iejycfxtez) = aekzkyjbcr lymweodqtu (jqlswwdslx )
Phase 2
140
Placebo
yogvrudtcs(mdddjzzogd) = aoelejmatl mmyqdzjifx (nkwywqtewb )
Negative
20 May 2008
yogvrudtcs(mdddjzzogd) = bhmlwniqhh mmyqdzjifx (nkwywqtewb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free